City: Yeonsu-gu, Incheon

Samsung Biologics is a fully integrated end-to-end service provider offering development and manufacturing services, all at one site. We provide highly tailored solutions to clients, while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals, Samsung Biologics is a trusted CDMO partner of choice and is uniquely able to provide seamless offerings from cell line development to final aseptic fill/finish for biologics. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demands, Samsung Biologics is constructing a fourth plant, which will further advance the company’s standing as the world’s largest manufacturing facility at a single site—holding a 604KL total capacity upon full completion in mid-2023. Our facilities are all cGMP compliant with bioreactors ranging from small to large scales. We continue to upgrade our capabilities to accommodate our clients by investing in single-use technology and additional aseptic filling capacity. Additionally, Samsung Biologics’ R&D Center in South San Francisco is equipped for high-quality cell line development, and our Sales Office in Ridgefield Park, New Jersey, enables the company to work in closer proximity to clients based in the U.S. and Europe. We are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Your Trusted CDMO Partner, Samsung Biologics | Samsung Biologics is a fully integrated CDMO partner of choice, providing highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals, we provide seamless offerings from cell-line development to final fill/finish at every stage for biopharmaceutical products. Our plants are cGMP compliant with a wide range of bioreactor scales to serve varying client needs and meet growing market demand. We hold a total capacity of 604KL at Bio Campus I, the world’s largest biomanufacturing site, and have announced plans to construct a fifth plant, which will be operational in April 2025. | Samsung Biologics (KRX: 207940.KS) is a global contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 784kL across five plants, Samsung Biologics leverages its technologies and expertise to advance diverse modalities, including antibody-drug conjugates (ADC), multispecific antibodies, fusion proteins, and mRNA vaccines. With over 5,000 employees, Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America facilitates support to clients based in the U.S. and Europe, while a sales office in Japan serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of high-quality products, as well as making sustainable business decisions for the betterment of society, global health, and the planet. For more information, please visit https://samsungbiologics.com/